Report Detail
Global Cellular Tumor Antigen p53 Market Insights, Forecast to 2025
- RnM3028176 |
- 26 February, 2019 |
- Global |
- 123 Pages |
- QYResearch |
- Pharma & Healthcare
The global Cellular Tumor Antigen p53 market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cellular Tumor Antigen p53 market based on company, product type, end user and key regions.
This report studies the global market size of Cellular Tumor Antigen p53 in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cellular Tumor Antigen p53 in these regions.
This research report categorizes the global Cellular Tumor Antigen p53 market by top players/brands, region, type and end user. This report also studies the global Cellular Tumor Antigen p53 market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Advaxis, Inc.
American Gene Technologies International Inc.
Aprea AB
Cellceutix Corporation
Critical Outcome Technologies Inc.
Eleos Inc.
ORCA Therapeutics B.V.
OSE Pharma SA
PCI Biotech Holding ASA
Quark Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Shenzen SiBiono GeneTech Co., Ltd.
SK Biopharmaceuticals Co., Ltd.
Tara Immuno-Oncology Therapeutics LLC
Z53 Therapeutics, LLC
Market size by Product
COTI-2
D-12PGJ3
APR-246
ATRN-502
Cenersen Sodium
MJ-05
MX-225
Others
Market size by End User
Ovarian Cancer
Prostate Cancer
Brain Cancer
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Cellular Tumor Antigen p53 market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cellular Tumor Antigen p53 market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cellular Tumor Antigen p53 companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cellular Tumor Antigen p53 submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Cellular Tumor Antigen p53 are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cellular Tumor Antigen p53 market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Cellular Tumor Antigen p53 Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Cellular Tumor Antigen p53 Market Size Growth Rate by Product
- 1.4.2 COTI-2
- 1.4.3 D-12PGJ3
- 1.4.4 APR-246
- 1.4.5 ATRN-502
- 1.4.6 Cenersen Sodium
- 1.4.7 MJ-05
- 1.4.8 MX-225
- 1.4.9 Others
- 1.5 Market by End User
- 1.5.1 Global Cellular Tumor Antigen p53 Market Size Growth Rate by End User
- 1.5.2 Ovarian Cancer
- 1.5.3 Prostate Cancer
- 1.5.4 Brain Cancer
- 1.5.5 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Cellular Tumor Antigen p53 Market Size
- 2.1.1 Global Cellular Tumor Antigen p53 Revenue 2014-2025
- 2.1.2 Global Cellular Tumor Antigen p53 Sales 2014-2025
- 2.2 Cellular Tumor Antigen p53 Growth Rate by Regions
- 2.2.1 Global Cellular Tumor Antigen p53 Sales by Regions
- 2.2.2 Global Cellular Tumor Antigen p53 Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Cellular Tumor Antigen p53 Sales by Manufacturers
- 3.1.1 Cellular Tumor Antigen p53 Sales by Manufacturers
- 3.1.2 Cellular Tumor Antigen p53 Sales Market Share by Manufacturers
- 3.1.3 Global Cellular Tumor Antigen p53 Market Concentration Ratio (CR5 and HHI)
- 3.2 Cellular Tumor Antigen p53 Revenue by Manufacturers
- 3.2.1 Cellular Tumor Antigen p53 Revenue by Manufacturers (2014-2019)
- 3.2.2 Cellular Tumor Antigen p53 Revenue Share by Manufacturers (2014-2019)
- 3.3 Cellular Tumor Antigen p53 Price by Manufacturers
- 3.4 Cellular Tumor Antigen p53 Manufacturing Base Distribution, Product Types
- 3.4.1 Cellular Tumor Antigen p53 Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Cellular Tumor Antigen p53 Product Type
- 3.4.3 Date of International Manufacturers Enter into Cellular Tumor Antigen p53 Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Cellular Tumor Antigen p53 Sales by Product
- 4.2 Global Cellular Tumor Antigen p53 Revenue by Product
- 4.3 Cellular Tumor Antigen p53 Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Cellular Tumor Antigen p53 Breakdown Data by End User
6 North America
- 6.1 North America Cellular Tumor Antigen p53 by Countries
- 6.1.1 North America Cellular Tumor Antigen p53 Sales by Countries
- 6.1.2 North America Cellular Tumor Antigen p53 Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Cellular Tumor Antigen p53 by Product
- 6.3 North America Cellular Tumor Antigen p53 by End User
7 Europe
- 7.1 Europe Cellular Tumor Antigen p53 by Countries
- 7.1.1 Europe Cellular Tumor Antigen p53 Sales by Countries
- 7.1.2 Europe Cellular Tumor Antigen p53 Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Cellular Tumor Antigen p53 by Product
- 7.3 Europe Cellular Tumor Antigen p53 by End User
8 Asia Pacific
- 8.1 Asia Pacific Cellular Tumor Antigen p53 by Countries
- 8.1.1 Asia Pacific Cellular Tumor Antigen p53 Sales by Countries
- 8.1.2 Asia Pacific Cellular Tumor Antigen p53 Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Cellular Tumor Antigen p53 by Product
- 8.3 Asia Pacific Cellular Tumor Antigen p53 by End User
9 Central & South America
- 9.1 Central & South America Cellular Tumor Antigen p53 by Countries
- 9.1.1 Central & South America Cellular Tumor Antigen p53 Sales by Countries
- 9.1.2 Central & South America Cellular Tumor Antigen p53 Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Cellular Tumor Antigen p53 by Product
- 9.3 Central & South America Cellular Tumor Antigen p53 by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Cellular Tumor Antigen p53 by Countries
- 10.1.1 Middle East and Africa Cellular Tumor Antigen p53 Sales by Countries
- 10.1.2 Middle East and Africa Cellular Tumor Antigen p53 Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Cellular Tumor Antigen p53 by Product
- 10.3 Middle East and Africa Cellular Tumor Antigen p53 by End User
11 Company Profiles
- 11.1 Advaxis, Inc.
- 11.1.1 Advaxis, Inc. Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Advaxis, Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Advaxis, Inc. Cellular Tumor Antigen p53 Products Offered
- 11.1.5 Advaxis, Inc. Recent Development
- 11.2 American Gene Technologies International Inc.
- 11.2.1 American Gene Technologies International Inc. Company Details
- 11.2.2 Company Business Overview
- 11.2.3 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Products Offered
- 11.2.5 American Gene Technologies International Inc. Recent Development
- 11.3 Aprea AB
- 11.3.1 Aprea AB Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Aprea AB Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Aprea AB Cellular Tumor Antigen p53 Products Offered
- 11.3.5 Aprea AB Recent Development
- 11.4 Cellceutix Corporation
- 11.4.1 Cellceutix Corporation Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Cellceutix Corporation Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Cellceutix Corporation Cellular Tumor Antigen p53 Products Offered
- 11.4.5 Cellceutix Corporation Recent Development
- 11.5 Critical Outcome Technologies Inc.
- 11.5.1 Critical Outcome Technologies Inc. Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Products Offered
- 11.5.5 Critical Outcome Technologies Inc. Recent Development
- 11.6 Eleos Inc.
- 11.6.1 Eleos Inc. Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Eleos Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Eleos Inc. Cellular Tumor Antigen p53 Products Offered
- 11.6.5 Eleos Inc. Recent Development
- 11.7 ORCA Therapeutics B.V.
- 11.7.1 ORCA Therapeutics B.V. Company Details
- 11.7.2 Company Business Overview
- 11.7.3 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Products Offered
- 11.7.5 ORCA Therapeutics B.V. Recent Development
- 11.8 OSE Pharma SA
- 11.8.1 OSE Pharma SA Company Details
- 11.8.2 Company Business Overview
- 11.8.3 OSE Pharma SA Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 OSE Pharma SA Cellular Tumor Antigen p53 Products Offered
- 11.8.5 OSE Pharma SA Recent Development
- 11.9 PCI Biotech Holding ASA
- 11.9.1 PCI Biotech Holding ASA Company Details
- 11.9.2 Company Business Overview
- 11.9.3 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Products Offered
- 11.9.5 PCI Biotech Holding ASA Recent Development
- 11.10 Quark Pharmaceuticals, Inc.
- 11.10.1 Quark Pharmaceuticals, Inc. Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Products Offered
- 11.10.5 Quark Pharmaceuticals, Inc. Recent Development
- 11.11 Stemline Therapeutics, Inc.
- 11.12 Shenzen SiBiono GeneTech Co., Ltd.
- 11.13 SK Biopharmaceuticals Co., Ltd.
- 11.14 Tara Immuno-Oncology Therapeutics LLC
- 11.15 Z53 Therapeutics, LLC
12 Future Forecast
- 12.1 Cellular Tumor Antigen p53 Market Forecast by Regions
- 12.1.1 Global Cellular Tumor Antigen p53 Sales Forecast by Regions 2019-2025
- 12.1.2 Global Cellular Tumor Antigen p53 Revenue Forecast by Regions 2019-2025
- 12.2 Cellular Tumor Antigen p53 Market Forecast by Product
- 12.2.1 Global Cellular Tumor Antigen p53 Sales Forecast by Product 2019-2025
- 12.2.2 Global Cellular Tumor Antigen p53 Revenue Forecast by Product 2019-2025
- 12.3 Cellular Tumor Antigen p53 Market Forecast by End User
- 12.4 North America Cellular Tumor Antigen p53 Forecast
- 12.5 Europe Cellular Tumor Antigen p53 Forecast
- 12.6 Asia Pacific Cellular Tumor Antigen p53 Forecast
- 12.7 Central & South America Cellular Tumor Antigen p53 Forecast
- 12.8 Middle East and Africa Cellular Tumor Antigen p53 Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Cellular Tumor Antigen p53 Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Cellular Tumor Antigen p53 . Industry analysis & Market Report on Cellular Tumor Antigen p53 is a syndicated market report, published as Global Cellular Tumor Antigen p53 Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Cellular Tumor Antigen p53 market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
